869884-78-6

Basic information

• Product Name: Radezolid
• Synonyms: radezolid;N-[[(5S)-3-[2-Fluoro-4'-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide;Unii-53pc6lo35w;RX 1741;RX-1741;N-[[(5S)-3-[2-Fluoro-4'-[[(1H-1,2,3-triazol-5-yLmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-ox;(5S)-N-[3-(2-fluoro-4'-{[(1H-[1,2,3]triazol-4-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]acetamide
• CAS NO: 869884-78-6
• Molecular Formula: C₂₂H₂₃FN₆O₃
• Molecular Weight: 438.45
• Mol File: 869884-78-6.mol

Chemical Properties

• Boiling Point: 712.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.336
• Solubility: ≥43.8 mg/mL in DMSO; insoluble in H2O; ≥18.08 mg/mL in EtOH with gentle warming
• PKA: 15.53±0.46(Predicted)
• CAS DataBase Reference: Radezolid(CAS DataBase Reference)
• NIST Chemistry Reference: Radezolid(869884-78-6)
• EPA Substance Registry System: Radezolid(869884-78-6)

Safety Data

• Hazardous Substances Data: 869884-78-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Radezolid is used as an antibiotic for the treatment of bacterial infections, particularly targeting Gram-positive bacteria, including drug-resistant strains such as MRSA and vancomycin-resistant enterococci. Its mechanism of action involves inhibiting bacterial protein synthesis, which has shown promising results in early clinical trials in terms of efficacy and safety.
Used in Combating Drug-Resistant Bacterial Infections:
Radezolid is employed as a treatment option for challenging bacterial infections caused by drug-resistant strains. Its unique chemical structure and mechanism of action may provide an advantage over existing oxazolidinone antibiotics, offering a new approach to managing and treating these infections.
Used in Clinical Trials:
Radezolid is utilized in clinical trials to evaluate its efficacy and safety in treating bacterial infections. Early trials have shown promising results, indicating its potential as a valuable addition to the arsenal of antibiotics for combating bacterial infections, especially those caused by drug-resistant strains.

Upstream product

• 627543-03-7 (5S)-5-aminomethyl-3-(3-fluoro-4-iodophenyl)-oxazolidin-2-one 
• 501939-82-8 (5R)-methanesulfonic acid 3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 149524-42-5 (5R)-3-(3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one 
• 149524-47-0 N-(carbobenzyloxy)-3-fluoroaniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 70978-37-9 1-(azidomethyl)-4-methoxybenzene 
• 87199-17-5 4-formylphenylboronic acid, 
• 2450-71-7 Propargylamine 
• 149524-45-8 (S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide 
• 372-19-0 meta-fluoroaniline 
• 916888-21-6 (5S)-N-{3-[2-fluoro-4'-({[1-(4-methoxybenzyl)-1H-[1,2,3]triazol-4-ylmethyl]amino}methyl)biphenyl-4-yl]-2-oxo-oxazolidin-5-ylmethyl}acetamide hydrochloride 

Downstream Products

• 869884-77-5 (5S)-N-[3-(2-fluoro-4'-{[(1H-[1,2,3]triazol-4-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]acetamide hydrochloride 

Relevant articles and documents

METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION

The present invention relates to methods for treating acne and other skin infections caused or mediated by Propionibacterium acnes, Gardnerella vaginalis, or Staphylococcus aureus in a patient with a safe and effective amount of a topically applied oxazolidinone antibiotic compound.

Process for the synthesis of triazoles

The present invention relates to processes for the preparation of triazoles. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

Design at the atomic level: Design of biaryloxazolidinones as potent orally active antibiotics

We have developed a first generation of hybrid sparsomycin-linezolid compounds into a new family of orally bioavailable biaryloxazolidinones that have activity against both linezolid-susceptible and -resistant Gram-positive bacteria as well as the fastidi